Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANW NASDAQ:AURA CVE:GPH NYSEMKT:IGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANWAegean Marine Petroleum Network$0.00$0.60▼$5.10$26.64M3.27526,099 shsN/AAURAAura Biosciences$6.77+3.1%$6.13$4.35▼$12.38$340.08M0.45209,108 shs113,303 shsGPHGraphite OneC$0.69C$0.77C$0.64▼C$1.07C$69.87M1.0272,229 shs10,100 shsIGCIGC Pharma$0.34+5.2%$0.32$0.25▼$0.50$30.34M1.45885,970 shs214,616 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-2.81%+4.96%+2.18%+21.48%-27.03%GPHGraphite One-1.43%+4.55%-10.39%-23.33%+2.99%IGCIGC Pharma-7.07%+5.56%+12.87%+19.16%+34,199,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANWAegean Marine Petroleum NetworkN/AN/AN/AN/AN/AN/AN/AN/AAURAAura Biosciences2.5676 of 5 stars3.61.00.00.03.33.30.0GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.6212 of 5 stars3.50.00.00.01.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANWAegean Marine Petroleum Network 0.00N/AN/AN/AAURAAura Biosciences 3.25Buy$22.00225.20% UpsideGPHGraphite One 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.881,029.74% UpsideCurrent Analyst Ratings BreakdownLatest ANW, GPH, IGC, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$22.005/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANWAegean Marine Petroleum Network$5.67B0.00N/AN/A$14.96 per share0.00AURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AIGCIGC Pharma$1.27M21.50N/AN/A$0.08 per share4.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANWAegean Marine Petroleum Network-$29.30M-$0.53N/A0.00N/AN/AN/AN/AN/AAURAAura Biosciences-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/14/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AIGCIGC Pharma-$13M-$0.08N/AN/AN/A-714.16%-122.44%-88.40%N/ALatest ANW, GPH, IGC, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANWAegean Marine Petroleum Network$0.034.58%N/AN/A N/AAURAAura BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANWAegean Marine Petroleum NetworkN/AN/AN/AAURAAura BiosciencesN/A11.0611.06GPHGraphite One0.021.090.33IGCIGC Pharma0.021.150.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANWAegean Marine Petroleum Network34.60%AURAAura Biosciences96.75%GPHGraphite One0.07%IGCIGC Pharma3.87%Insider OwnershipCompanyInsider OwnershipANWAegean Marine Petroleum NetworkN/AAURAAura Biosciences5.40%GPHGraphite One28.81%IGCIGC Pharma31.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANWAegean Marine Petroleum NetworkN/A40.64 millionN/AOptionableAURAAura Biosciences5050.27 million47.55 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AANW, GPH, IGC, and AURA HeadlinesRecent News About These CompaniesIGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict ...July 12, 2025 | morningstar.comMIGC Pharma, Inc.: IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early DetectionJuly 11, 2025 | finanznachrichten.deIGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early DetectionJuly 10, 2025 | accessnewswire.comAEarnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.comJuly 2, 2025 | investing.comIGC Pharma earnings matched, revenue fell short of estimatesJuly 2, 2025 | investing.comEarnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.com UKJuly 2, 2025 | uk.investing.comIGC Pharma, Inc.: IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's InnovationJune 30, 2025 | finanznachrichten.deIGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's InnovationJune 30, 2025 | accessnewswire.comAIGC Pharma, Inc.: IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - FinanzNachrichten.deJune 28, 2025 | finanznachrichten.deIGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - MorningstarJune 28, 2025 | morningstar.comMIGC Pharma Inc Trailing Returns - MorningstarJune 27, 2025 | morningstar.comMIGC Pharma Inc. Annual Cash Flow Statement - MarketWatchJune 27, 2025 | marketwatch.comInsights Ahead: IGC Pharma's Quarterly EarningsJune 27, 2025 | benzinga.comIGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue EstimatesJune 27, 2025 | zacks.comIGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025June 27, 2025 | accessnewswire.comAIGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon - MorningstarJune 24, 2025 | morningstar.comMIGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in YukonJune 23, 2025 | accessnewswire.comAIGC Pharma, Inc.: IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's MarketMay 22, 2025 | finanznachrichten.deOtsuka Holdings Stock Price, Quotes and Forecasts | OTC:OTSKY | BenzingaMay 22, 2025 | benzinga.comIGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's MarketMay 22, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseExpect Robust Growth From These 3 Cybersecurity LeadersBy Thomas Hughes | July 16, 2025View Expect Robust Growth From These 3 Cybersecurity LeadersANW, GPH, IGC, and AURA Company DescriptionsAegean Marine Petroleum Network NYSE:ANWAegean Marine Petroleum Network Inc., together with its subsidiaries, operates as a marine fuel logistics company that markets and supplies refined marine fuel and lubricants to vessels in port, at sea, and on rivers worldwide. The company offers fueling services to ocean-going and a range of coastal vessels, including oil tankers, container ships, drybulk carriers, cruise ships, reefers, LNG/LPG carriers, car carriers, and ferries, as well as to marine fuel traders, brokers, and other end-users of marine fuel and lubricants. It also markets and distributes marine lubricants under the Alfa Marine Lubricants brand; and provides a range of shipping services, such as technical support and maintenance, insurance arrangement and handling, financial administration, and accounting services. As of December 31, 2016, the company owned and operated a fleet of 46 bunkering vessels, including 45 double hulls and 1 single hull special purpose vehicle; 15 double hull bunkering vessels with an aggregate carrying capacity of approximately 292,400 deadweight ton (dwt); operated 10 land-based storage facilities with an aggregate storage capacity of approximately 1,075,000 cubic meters; and operated 2 vessels as floating storage facility with a cargo carrying capacity of approximately 86,800 dwt. Aegean Marine Petroleum Network Inc. was founded in 1995 and is headquartered in Athens, Greece.Aura Biosciences NASDAQ:AURA$6.76 +0.21 (+3.13%) As of 12:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Graphite One CVE:GPHC$0.69 0.00 (0.00%) As of 11:51 AM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.34 +0.02 (+5.18%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
